ALL DRUG CODES

ALL CODES   A CODE    B CODE    C CODE    CPT CODE    J CODE    NOC CODE    P CODE    Q CODE    S CODE   COST

TOFIDENCE – Q5133

TOFIDENCE is manufactured by Biogenand aligned to the Q Code: Q5133. TOFIDENCE is a Immunosuppressant medication administered via the Intravenous route of administration.

Read More »

TYRUKO – Q5134

TYRUKO is manufactured by Sandozand aligned to the Q Code: Q5134. TYRUKO is a Neurology medication administered via the Intravenous route of administration.

Read More »

Veopoz – J9376

Veopoz is manufactured by REGENERON PHARMACEUTICALSand aligned to the J Code: J9376. Veopoz is a Immunosuppressant medication administered via the Intravenous route of administration.

Read More »

Focinvez – J1434

Focinvez is manufactured by Spes Pharmaceuticalsand aligned to the J Code: J1434. Focinvez is a Antiemetic medication administered via the Intravenous route of administration.

Read More »

Cyanokit – J3424

Cyanokit is manufactured by SERB Pharmaceuticalsand aligned to the J Code: J3424. Cyanokit is a Cyanide Antidote medication administered via the Intravenous route of administration.

Read More »

HEPZATO – J9248

HEPZATO is manufactured by Delcathand aligned to the J Code: J9248. HEPZATO is a Alkylating agent medication administered via the Intravenous route of administration.

Read More »

Melphalan (Apotex) – J9249

Melphalan (Apotex) is manufactured by Apotexand aligned to the J Code: J9249. Melphalan (Apotex) is a Alkylating agent medication administered via the Intravenous route of administration.

Read More »

Sodium Thiosulfate – J0209

Sodium Thiosulfate is manufactured by Hope Pharmaceuticalsand aligned to the J Code: J0209. Sodium Thiosulfate is a Antidote medication administered via the Intravenous route of administration.

Read More »

Levothyroxine Sodium – J0650

Levothyroxine Sodium is manufactured by Multiple Manufacturersand aligned to the J Code: J0650. Levothyroxine Sodium is a Hormone medication administered via the Oral route of administration.

Read More »

RYKINDO – J2801

RYKINDO is manufactured by SHANDONG LUYE PHARMACEUTICALSand aligned to the J Code: J2801. RYKINDO is a Antipsychotic medication administered via the Intramuscular route of administration.

Read More »

CUVITRU – Cost

Cuvitru’s HCPCS code, J1555, was both added and became effective on January 1, 2018. Cuvitru’s AWP has risen moderately over the years, typically increasing slightly every six months to a year. The price has increased by larger increments in recent years, with larger price hikes January 2022, December 2022, and December 2023. The WAC has followed the same trends as the AWP, with regular, slight price increases, and larger, yearly increases in recent years. The ASP typically fluctuates month to month, but stays mostly around the same price. There is a more considerable gap between the ASP and the WAC, between 30 and 40%.

Read More »

ETHAMOLIN – Cost

Ethamolin’s HCPCS code, J1430, was added and became effective on January 1, 2006. Ethamolin’s AWP saw a very sharp price increase in November 2016, then entered a long period of stagnant pricing between November 2016 and September 2021. Since September 2021, the AWP has seen slight price increases each year in January. The WAC has followed the same trends as the ASP, with no price changes between November 2016 and September 2021, then a period of predictable price increases since September 2021. The ASP remained at a consistent level between January 2016 and March 2017, then saw two sharp price increases in April and July of 2017. The ASP remained at a consistent price for a long period between July 2017 and March 2022. Since March 2022, the ASP has seen two price increases and one slight decrease, along with slight monthly fluctuations.

Read More »

GRANIX – Cost

Granix’s HCPCS code, J1447, was added and became effective on January 1, 2016. Granix’s AWP has remained at the same price since 2016. The WAC has also remained at a consistent level since the drug’s code was added. The ASP has fluctuated month to month, but has followed an overall downward trend, decreasing in price over time. This decrease in price has led to a significant gap between then WAC and the ASP, with the ASP currently being about half of the WAC as of April 2024.

Read More »

INJECTAFER – Cost

Injectafer’s HCPCS code, J1439, was added and became effective on January 1, 2015. Between January 2016 and June 2018, Injectafer’s AWP saw a few slight increases and one slight decrease. Then, between July 2018 and January 2021, the AWP remained mostly consistent, with one slight price increase in March 2019. Between January 2021 and March 2024, the AWP increased every few months, with some sharper increases and some more moderate. The WAC has followed the same trends as the AWP. The ASP has remained at a fairly consistent level over the years, with very slight monthly fluctuations. Since the WAC has risen gradually over time, this has led to a significant gap between the WAC and the ASP.

Read More »

Monoferric – Cost

Monoferric’s HCPCS code, J1437, was added on October 1, 2020. It became effective on January 1, 2023. Between October 2020 and December 2021, the WAC remained at a consistent price. The WAC saw slight price increases in December 2021 and August 2022, then sharper increases April 2023 and December 2023. The WAC has followed the same trends, beginning with a period of consistent pricing, then slight increases followed by a few sharper increases. The ASP began in very close the price of the WAC in July 2021, but has slowly decreased over time, leaving a considerable gap between the ASP and the WAC.

Read More »

NEUPOGEN – Cost

Neupogen’s HCPCS code, J1442, was added on January 1, 2014, and became effective on January 1, 2016. The AWP remained mostly consistent between January 2016 and March 2024, with one slight price increase in November 2017. The WAC has also been mostly consistent in price, with one slight increase in November 2017. The ASP has many fluctuations month to month, but remained around a consistent level between January 2016 and March 2018. The AWP began to climb slightly between March 2018 and September 2018, then steadily declined until December 2020. The AWP then began to climb steadily until August 2022, then began to even out to a fairly consistent level. Despite these fluctuations, the ASP and the WAC have remained fairly close in price, between 2-4%.

Read More »

PREMARIN – Cost

Premarin’s HCPCS code, J1410, was added on January 1, 1982. However, it did not become effective until January 1, 2017. Premarin’s AWP saw a few sharp price increases between January 2016 and December 2017, then entered into a stagnant period where it remained at the same level between January 2018 and December 2019. Beginning in January 2020, Premarin’s WAC entered a period of predictable pricing, with a moderate raise in price once per year in January. The WAC has followed the same trend as the AWP, with a long period of stagnant pricing between January 2018 and December 2019, and predictable yearly price increases between January 2020 and March 2024. The ASP has followed the WAC’s trends, however the increases in the price of the ASP typically happen a few months after the WAC increases.

Read More »

REBYOTA – Cost

Rebyota’s HCPCS code is J1440. It was added and became effective on July 1, 2023. Reboyta’s AWP has remained at a consistent price since July 2023. The WAC has also remained at a consistent level since the drug’s debut. The ASP has remained at a consistent level close to the WAC since October 2023, within 2% of the price.

Read More »